Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
92 hedge funds and large institutions have $1.06B invested in Verve Therapeutics in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 23 reducing their positions, and 23 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 23
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2.27% more ownership
Funds ownership: 93.75% → 96.02% (+2.3%)
4% less funds holding
Funds holding: 96 → 92 (-4)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
36% less capital invested
Capital invested by funds: $1.66B → $1.06B (-$598M)
83% less call options, than puts
Call options by funds: $212K | Put options by funds: $1.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.3M |
| 2 |
BlackRock
New York
|
+$26.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$45.5M |
| 2 |
Jennison Associates
New York
|
-$16.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$13.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$11.4M |
VERV Hedge Fund Activity: Q1 2022 in Review
92 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q1 2022, worth a combined $1.06B — down 36% from $1.66B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of VERV and 19 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 39 added.
The largest buyer was Vanguard Group, adding an estimated $27.3M. The largest seller was Wellington Management Group, cutting an estimated $45.5M.
- 92 institutional investors held Verve Therapeutics (VERV) as of Q1 2022, down from 96 in Q4 2021.
- Funds reported $1.06B of Verve Therapeutics stock for Q1 2022, down 36% quarter-over-quarter.
- 19 funds opened new Verve Therapeutics positions in Q1 2022 and 23 closed out, a net change of -4 holders.
- The largest Verve Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $27.3M added.
- The largest Verve Therapeutics seller in Q1 2022 was Wellington Management Group, an estimated $45.5M sold.
Based on aggregated 13F filings for Q1 2022.